The company remains in a persistent cash-burning state, with free cash flow deficits reaching $34.2 million in 2026Q1 and an OCF/NI ratio that has fluctuated as low as 0.16 in recent periods.
| Cash from Operations | -101M | -150.79M | -214.87M | -198.18M | -367.64M | -549.23M | -216.06M | -191.01M | -97.54M | -32.37M | -32.16M | -11.46M |
| Operating CF Margin % | - | -32.77% | -53.85% | -74.3% | -170.96% | -380.59% | -441.31% | -1471.04% | -75346.86% | - | - | - |
| Operating CF Growth % | 141% | 29.82% | -8.42% | 46.09% | 33.06% | -154.21% | -13.11% | -95.83% | -201.35% | -0.65% | -180.49% | - |
| Net Income | -178.12M | -175.54M | -257.1M | -334.62M | -443.29M | -704.47M | -268.9M | -195.07M | -139.07M | -50.38M | -37.51M | -18.02M |
| Depreciation & Amortization | 15.5M | 15.01M | 11.86M | 9.03M | 8.23M | 6.49M | 4.64M | 3.77M | 1.65M | 548.13K | 199K | 126.51K |
| Stock-Based Compensation | 63.32M | 65.6M | 70.65M | 79.63M | 61.3M | 40.71M | 24.83M | 20.29M | 12.23M | 9.93M | 4.93M | 2.7M |
| Deferred Taxes | 0 | -3.34M | 0 | 0 | 0 | 17.08M | 1.13M | 767K | 587.25K | 0 | 0 | 0 |
| Other Non-Cash Items | -17.8M | -1.02M | 28.12M | 8.17M | 72.36M | 67.85M | 4.01M | 2.52M | -312K | 62.61K | 1.92M | 2.02M |
| Working Capital Changes | 16.1M | -51.51M | -68.39M | 39.61M | -66.25M | 23.11M | 18.25M | -23.28M | 27.38M | 7.48M | -1.69M | 1.71M |
| Change in Receivables | 25.84M | -26.72M | -26.58M | -17.69M | 25.14M | -42.32M | -1.38M | -3.7M | -89.71K | 0 | 0 | 0 |
| Change in Inventory | -45.04M | -47.15M | 3.9M | -14.91M | -15.38M | -7.17M | -7.17M | -6M | -3.82K | 0 | 0 | 0 |
| Change in Payables | 21.47M | 19.93M | -2.21M | 36.8M | -53.77M | 63.52M | 39.98M | -14.77M | 28.46M | 8.44M | -929.72K | 1.29M |
| Cash from Investing | -40.55M | 307.87M | -375.19M | -10.78M | 420.02M | 249.96M | -554.83M | -14.89M | -212.55M | -10.43M | -2.73M | -738.47K |
| Capital Expenditures | -7.76M | -8.1M | -5.66M | -7.21M | -24.59M | -18.95M | -10.67M | -15.24M | -10.12M | -9.12M | -2.23M | -738.47K |
| CapEx % of Revenue | 1.71% | 1.76% | 1.42% | 2.7% | 11.43% | 13.13% | 21.79% | 117.38% | 7815.9% | - | - | - |
| Acquisitions | 0 | 0 | 29K | 0 | 0 | -30M | 539K | 9.21M | -2.09M | -1.9M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -34M | -5.24M | -55.86M | 12.74M | -399K | 3K | -539K | -9.21M | -102.83K | 68.1K | -505.62K | 0 |
| Cash from Financing | 34.78M | 72.35M | 349.89M | -6.43M | -1.73M | 820.2M | 1.13B | 219.3M | 144.15M | 187.86M | 106.2M | 18.28M |
| Debt Issued (Net) | 34.07M | 68.12M | 131.32M | 0 | 0 | 0 | -6.53M | 2.9M | 3.64M | 0 | 0 | 0 |
| Equity Issued (Net) | 9.54M | 12.85M | 217.35M | 0 | 0 | 818.88M | 1.14B | 216.2M | 141M | 189.53M | 106.2M | 18.28M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -8.83M | -8.63M | 1.22M | -6.43M | -1.73M | 1.33M | 1.28M | 201K | -496.2K | -1.67M | 0 | 0 |
| Net Change in Cash | -105.94M | 229.91M | -240.48M | -218.01M | 44.37M | 522.04M | 366.42M | 13.49M | -166.71M | 145.71M | 70.79M | 6.01M |
| Free Cash Flow | -129.23M | -158.89M | -276.39M | -206.67M | -392.63M | -568.18M | -226.72M | -206.25M | -107.66M | -41.48M | -34.39M | -12.2M |
| FCF Margin % | -28.51% | -34.53% | -69.27% | -77.49% | -182.58% | -393.72% | -463.1% | -1588.42% | -83162.76% | - | - | - |
| FCF Growth % | 45.89% | 42.51% | -33.74% | 47.36% | 30.9% | -150.6% | -9.93% | -91.59% | -159.51% | -20.64% | -181.79% | - |
| FCF per Share | -1.17 | -1.45 | -2.79 | -21.39 | -40.98 | -61.10 | -29.19 | -32.04 | -20.46 | -19.07 | -36.43 | -14.04 |
| FCF Conversion (FCF/Net Income) | 0.73x | 0.86x | 0.84x | 0.59x | 0.83x | 0.78x | 0.80x | 0.98x | 0.70x | 0.64x | 0.86x | 0.64x |
| Interest Paid | -1.1M | 0 | 2.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Persistent Operational Cash Burn
As reported in recent financial filings, Zai Lab's operating cash flow frequently diverges from net income, with the OCF/NI ratio fluctuating wildly between 0.16 and 1.69, suggesting that accounting accruals and non-cash adjustments significantly obscure the underlying cash-generating capacity of the firm's core pharmaceutical operations.
The lack of a consistent relationship between net income and operating cash flow indicates that the company's reported losses do not fully capture the cash-intensive nature of its licensing-heavy business model. Investors should monitor whether this volatility stems from lumpy milestone payments or shifts in working capital, as it complicates the assessment of true operational sustainability.
Based on the company's reported figures, Zai Lab continues to experience significant free cash flow deficits, with quarterly outflows reaching as high as $103.1 million, reflecting a persistent inability to fund its expansive R&D and commercial infrastructure through internal cash generation alone.
The consistent negative FCF margins, which have occasionally exceeded 100% of revenue, highlight the company's reliance on external capital to bridge the gap between its high fixed-cost structure and current revenue levels. This trajectory suggests that the firm remains in a capital-intensive growth phase that may require further financing if operational efficiencies do not materialize.
According to quarterly cash flow statements, Zai Lab exhibits erratic working capital swings, including a notable $57.2 million outflow in 2024Q1 followed by a $35.9 million inflow in 2026Q1, which indicates significant sensitivity to inventory management and the timing of payments to its global licensing partners.
These fluctuations suggest that the company's cash position is highly susceptible to the timing of commercial cycles and the settlement of obligations related to its licensed portfolio. Such volatility warrants further investigation into whether these movements represent structural shifts in supply chain efficiency or merely the timing of large, non-recurring payments.
Data from recent SEC filings reveals that stock-based compensation consistently exceeds $13 million per quarter, effectively acting as a non-cash substitute for salary expenses that would otherwise exacerbate the company's already significant operational cash burn and dilute existing shareholders' equity over the long term.
While SBC is a standard tool for talent retention in the competitive Shanghai biotech market, its magnitude relative to the company's negative operating cash flow suggests that the true cost of operations is higher than the cash flow statement implies. Investors should consider this as a hidden operational expense that masks the full extent of the firm's cash requirements.
Quick answers to the most common questions about buying ZLAB stock.
Zai Lab Limited (ZLAB) generated $-150.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Zai Lab Limited (ZLAB) reported negative free cash flow of $158.9M in 2025, indicating capital requirements exceeded cash from operations.
Zai Lab Limited (ZLAB) spent $8.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.